TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma

Clinical trial NCT03722342 · UNKNOWN

Trial details

NCT number: NCT03722342
Sponsor: PharmAbcine
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Glioblastoma

Start date: 2019-01-16
Primary completion: 2019-11-04
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.